William Blair analyst Myles Minter has reiterated their bullish stance on AXSM stock, giving a Buy rating today.
Myles Minter’s rating is based on the positive outcomes from Axsome Therapeutics’ recent Phase III FOCUS trial, which evaluated solriamfetol in adults with ADHD. The trial demonstrated that the 150 mg dose of solriamfetol achieved a statistically significant reduction in the AISRS total score compared to placebo, with improvements observed as early as the first week. This dose also showed significant results in the Clinical Global Impression of Severity, a key secondary endpoint.
The promising results of the FOCUS study add to Axsome’s string of successes, with upcoming data on major depressive disorder (MDD) expected to further bolster the company’s prospects. The positive trajectory of Axsome’s clinical trials and the potential expansion of their therapeutic offerings underpin Minter’s Buy rating, positioning the company as a top pick for 2025.
Minter covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Verve Therapeutics, and Entrada Therapeutics Inc. According to TipRanks, Minter has an average return of 5.9% and a 45.68% success rate on recommended stocks.
In another report released today, Needham also maintained a Buy rating on the stock with a $153.00 price target.